These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34861783)

  • 1. Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States.
    Khatri A; Shelke R; Guan S; Somanathan S
    Hum Gene Ther; 2022 Apr; 33(7-8):442-450. PubMed ID: 34861783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans.
    Ellsworth JL; O'Callaghan M; Rubin H; Seymour A
    Hum Gene Ther Clin Dev; 2018 Mar; 29(1):60-67. PubMed ID: 29624457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
    Sierra-Delgado JA; Likhite S; Bautista PK; Gómez-Ochoa SA; Echeverría LE; Guío E; Vargas C; Serrano NC; Meyer KC; Rincon MY
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.
    Kashiwakura Y; Baatartsogt N; Yamazaki S; Nagao A; Amano K; Suzuki N; Matsushita T; Sawada A; Higasa S; Yamasaki N; Fujii T; Ogura T; Takedani H; Taki M; Matsumoto T; Yamanouchi J; Sakai M; Nishikawa M; Yatomi Y; Yada K; Nogami K; Watano R; Hiramoto T; Hayakawa M; Kamoshita N; Kume A; Mizukami H; Ishikawa S; Sakata Y; Ohmori T
    Mol Ther Methods Clin Dev; 2022 Dec; 27():404-414. PubMed ID: 36381300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.
    Kotterman MA; Yin L; Strazzeri JM; Flannery JG; Merigan WH; Schaffer DV
    Gene Ther; 2015 Feb; 22(2):116-26. PubMed ID: 25503696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of adeno-associated virus neutralizing antibody activity for clinical application.
    Wang M; Crosby A; Hastie E; Samulski JJ; McPhee S; Joshua G; Samulski RJ; Li C
    Gene Ther; 2015 Dec; 22(12):984-92. PubMed ID: 26125606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India.
    Daniel HD; Kumar S; Kannangai R; Lakshmi KM; Agbandje-Mckenna M; Coleman K; Srivastava A; Srivastava A; Abraham AM
    Hum Gene Ther; 2021 May; 32(9-10):451-457. PubMed ID: 33207962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays.
    Gorovits B; Fiscella M; Havert M; Koren E; Long B; Milton M; Purushothama S
    AAPS J; 2020 Jan; 22(2):24. PubMed ID: 31907680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Gene Therapy Vectors: Remaining Challenges.
    Gupta V; Lourenço SP; Hidalgo IJ
    J Pharm Sci; 2021 May; 110(5):1915-1920. PubMed ID: 33279518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
    Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
    Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing Antibodies Against Adeno-Associated Virus (AAV): Measurement and Influence on Retinal Gene Delivery.
    Desrosiers M; Dalkara D
    Methods Mol Biol; 2018; 1715():225-238. PubMed ID: 29188517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.